Clinical trials: completed, in Georgia
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Relapsed Small Cell Lung Cancer
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of…
- Trial name
- NCT05153239
- Testing
- Irinotecan, Lurbinectedin, Topotecan
- Where
- 210 sites in United States, Australia and 22 more
- Volunteers
- 705 people
- Sponsor
- PharmaMar
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication.
- Trial name
- NCT07037875
- Testing
- Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD)
- Where
- 87 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 523 people
- Sponsor
- Cinclus Pharma Holding AB
Moderate-to-Severe Atopic Dermatitis
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
- Trial name
- NCT03989206
- Testing
- Nemolizumab
- Where
- 343 sites in United States, Australia and 20 more
- Volunteers
- 1,935 people
- Sponsor
- Galderma R&D
Melanoma, Stage II, Melanoma Stage III
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
Melanoma is a kind of skin cancer that starts in the melanocytes. Melanocytes are cells that make the pigment that gives skin its colour. 'Resected' means the melanoma has been completely removed with surgery.
- Trial name
- Dahlia (NCT06551064)
- Testing
- FYB206, Keytruda
- Where
- 17 sites in Bosnia and Herzegovina, Bulgaria and 9 more
- Volunteers
- 96 people
- Sponsor
- Formycon AG
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- EMERALD-2 (NCT05611671)
- Testing
- MORF-057
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 280 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the…
- Trial name
- AERIFY-1 (NCT04701983)
- Testing
- Itepekimab SAR440340
- Where
- 232 sites in United States, Argentina and 19 more
- Volunteers
- 1,127 people
- Sponsor
- Sanofi
Atopic Dermatitis, Eczema
Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with erythema, scaly and oozing plaques, and severe pruritus which has an important impact on quality of life and quality of sleep.
- Trial name
- NCT06930365
- Testing
- Anti-itching and repairing treatment. Emollient., Emollient cream
- Where
- Georgia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- NAOS Les Laboratoires
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with…
- Trial name
- AERIFY-2 (NCT04751487)
- Testing
- Itepekimab SAR440340
- Where
- 238 sites in United States, Argentina and 27 more
- Volunteers
- 1,234 people
- Sponsor
- Sanofi
Amenorrhea, Oligomenorrhea
Treatment of Menstrual Cycle Alterations in Adolescents
the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.
- Conditions
- Amenorrhea, Oligomenorrhea, PCOS (Polycystic Ovary Syndrome)
- Trial name
- HP-phD_Adolesc (NCT06800170)
- Testing
- myo-Inositol plus DIoscorea Villosa
- Where
- 2 sites in Georgia, Russia
- Volunteers
- 41 people
- Sponsor
- Lo.Li.Pharma s.r.l
Rheumatoid Arthritis (RA)
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
- Trial name
- NCT06596772
- Testing
- MB04 (proposed biosimilar to etanercept), Enbrel (etanercept)
- Where
- 60 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 501 people
- Sponsor
- mAbxience Research S.L.
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Osteoporosis, Postmenopausal
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
- Trial name
- NCT04729621
- Testing
- TVB-009, Prolia®
- Where
- 78 sites in United States, Bulgaria and 8 more
- Volunteers
- 332 people
- Sponsor
- Teva Pharmaceuticals USA
Head and Neck Cancer
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in…
- Trial name
- NCT05287113
- Testing
- Retifanlimab, INCAGN02385, INCAGN02390
- Where
- 91 sites in United States, Belgium and 12 more
- Volunteers
- 176 people
- Sponsor
- Incyte Biosciences International Sàrl
Type 2 Diabetes Mellitus (T2DM), Recurrent Urinary Tract Infections
Cranberry Proanthocyanidins and Lactobacilli for Recurrent UTI Prevention in Type 2 Diabetes
The purpose of this prospective, single-arm feasibility study was to evaluate the operational feasibility, tolerability, safety, and exploratory clinical outcomes of an oral supplement combining standardized cranberry…
- Trial name
- NCT07832409
- Testing
- Cranberry Proanthocyanidins and Lactobacilli
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- National Institute of Endocrinology, Georgia
Active Idiopathic Inflammatory Myopathy, Myositis
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM).
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA (NCT05523167)
- Testing
- EFG PH20 SC, PBO
- Where
- 202 sites in United States, Argentina and 34 more
- Volunteers
- 265 people
- Sponsor
- argenx
Carcinoma, Ductal, Breast, Breast Cancer Female
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader (SERD) alone and in combination with palbociclib, a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, in…
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer
- Trial name
- NCT03455270
- Testing
- G1T48, Palbociclib
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Diabetes
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-2982 at three different daily doses vs. placebo and sitagliptin 100 mg when administered for up to 4 weeks in patients that are treatment-naive…
- Trial name
- NCT01035879
- Testing
- MBX-2982, Sitagliptin
- Where
- 14 sites in United States, Georgia and 1 more
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
- Trial name
- AERIFY-4 (NCT06208306)
- Testing
- Itepekimab (SAR440340)
- Where
- 223 sites in United States, Argentina and 30 more
- Volunteers
- 669 people
- Sponsor
- Sanofi
Ulcerative Colitis
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative…
- Trial name
- SELECTIONLTE (NCT02914535)
- Testing
- Filgotinib
- Where
- 323 sites in United States, Argentina and 37 more
- Volunteers
- 1,173 people
- Sponsor
- Alfasigma S.p.A.